Validity of [123I]β‐CIT SPECT in detecting MDMA‐induced serotonergic neurotoxicity

Recent [123I]β‐CIT single‐photon emission computed tomography (SPECT) studies revealed decreased serotonin transporters (SERT) density in the brain of humans with a history of MDMA (“Ecstasy”) use. However, [123I]β‐CIT SPECT has until now not been validated as a method for detecting such serotonergic lesions. Therefore, the present study was undertaken. Following baseline [123I]β‐CIT SPECT scans, a rhesus monkey was treated with MDMA (5 mg/kg, s.c. twice daily for 4 consecutive days). SPECT studies 4, 10, and 31 days after MDMA treatment revealed decreases in [123I]β‐CIT binding ratios in the SERT‐rich brain region studied (hypothalamic/midbrain region), with SERT density reduced by 39% in this brain region 31 days after treatment. Data obtained with SPECT studies correlated well with SERT density determined with autoradiography after sacrifice of the animal (−34%). In addition, ex vivo [123I]β‐CIT binding studies in rats 1 week after treatment with neurotoxic doses of MDMA (20 mg/kg s.c. twice daily for 4 consecutive days) revealed significant reductions in [123I]β‐CIT binding in SERT‐rich regions (including the hypothalamus) when compared to saline‐treated rats. The combined results of these studies indicate that SPECT imaging of SERT with [123I]β‐CIT can detect changes in SERT density secondary to MDMA‐induced neurotoxicity in the hypothalamic/midbrain region, and possibly other brain regions. Synapse 46:199–205, 2002. © 2002 Wiley‐Liss, Inc.

[1]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[2]  G. Ricaurte,et al.  Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  J. Langston,et al.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.

[4]  E. Ronken,et al.  In vitro and in vivo characterization of newly developed iodinated 1‐{2‐[Bis(4‐fluorophenyl)methoxy]ethyl}piperazine derivatives in rats: Limited value as dopamine transporter SPECT ligands , 1996, Synapse.

[5]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.

[6]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. , 1996, The Journal of pharmacology and experimental therapeutics.

[7]  W. Lovenberg,et al.  Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. , 1986, European journal of pharmacology.

[8]  Liesbeth Reneman,et al.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons , 2001, The Lancet.

[9]  W. Slikker,et al.  Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). , 1988, Toxicology and applied pharmacology.

[10]  D. Jenden,et al.  Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[12]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[13]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[14]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[15]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[16]  W. van den Brink,et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.

[17]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[18]  G. Ricaurte,et al.  Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.

[19]  John Hilton,et al.  Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[20]  M. Kuhar,et al.  Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: In vivo studies with [125i]rti‐55 , 1994, Synapse.

[21]  Z. Szabo,et al.  In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.

[22]  M. Fujita,et al.  Enhancement of [123I]β-CIT binding in the striatum with clomipramine: Is there a serotonin-dopamine interaction? , 1997, European Journal of Nuclear Medicine.

[23]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[24]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  L. Parsons,et al.  Functional Consequences of Repeated (±)3,4-Methylenedioxymethamphetamine (MDMA) Treatment in Rhesus Monkeys , 2001, Neuropsychopharmacology.

[26]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  M. Kuhar,et al.  [123/125I]RTI‐55, an in vivo label for the serotonin transporter , 1992, Synapse.

[28]  F I Carroll,et al.  High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.

[29]  Klaus P. Ebmeier,et al.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.

[30]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[31]  J. Booij,et al.  [123I]FP‐CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP‐lesioned monkeys , 1997, Synapse.

[32]  Comparative in vivo study of iodine‐123‐labeled β‐cit and nor‐β‐cit binding to serotonin transporters in rat brain , 1999, Synapse.

[33]  J. Joyce,et al.  Comparison of [3H]Paroxetine and [3H]Cyanoimipramine for Quantitative Measurement of Serotonin Transporter Sites in Human Brain , 1996, Neuropsychopharmacology.